Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026GlobeNewsWire · 3 days ago
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel CoatsGlobeNewsWire · 6 days ago
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026GlobeNewsWire · Oct 9, 2026
Mineralys (NASDAQ: MLYS) CEO sells 75,000 shares under prearranged planDefense World · Oct 4, 2026
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026GlobeNewsWire · Oct 2, 2026
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026GlobeNewsWire · Oct 1, 2026Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.55 | -$2.85 | Miss |
| May 6, 2026 | -$0.51 | -$0.47 | Beat |
| Mar 12, 2026 | -$0.52 | -$0.40 | Beat |
| Nov 10, 2025 | -$0.66 | -$0.52 | Beat |
| Aug 12, 2025 | -$0.78 | -$0.66 | Beat |
| May 12, 2025 | -$1.02 | -$0.79 | Beat |